At first glance it appears that little has happened in our understanding of bronchogenic carcinoma, since five year survival rates have not changed appreciably over the past ten years. This is partially true, however the depth of our understanding has increased and will continue to do so at a rapid pace over the next five to ten years. Information on the basic tumor biology, identification of important groups at high risk and im proved delivery of cytotoxic agents in the treatment of lung cancer, will all add to improve the outcome. The purpose of this text is to provide useful background...